JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2022, 71(6):251-258 | DOI: 10.5817/CSF2022-6-251

Dose dumping of modified-release solid oral dosage forms

Tomáš Bílik, Miroslava Pavelková, Kateřina Kubová, Jakub Vysloužil*
Masarykova Univerzita, Farmaceutická fakulta, Ústav farmaceutické technologie, Brno

The presented review article is a compilation of several foreign reviews and experimental papers, as well as several authority guidelines, which deal with the phenomenon of dose dumping of solid dosage forms with modified drug release. The aim of the publication is to present this often-neglected issue to a wider domestic audience. The work deals with two basic types of dose dumping, i.e., alcohol-induced dose dumping and food-induced dose dumping. It contains basic factors affecting this phenomenon as well as possible formulation solutions that can be used to eliminate it. Last but not least, the current requirements of the authorities are also mentioned, especially for testing newly introduced products with the presumed potential risk of dose dumping.

Keywords: alcohol; dose dumping; modified release; modified release dosage forms

Received: October 4, 2022; Accepted: November 10, 2022; Published: June 1, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bílik T, Pavelková M, Kubová K, Vysloužil J. Dose dumping of modified-release solid oral dosage forms. Čes. slov. farm. 2022;71(6):251-258. doi: 10.5817/CSF2022-6-251.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Murray S., Wooltorton E. Alcohol-associated rapid release of a long-acting opioid. Cmaj. 2005; 173, 756-756. Go to original source... Go to PubMed...
    2. Walden M., Nicholls F. A., Smith K. J., Tucker, G. T. The Effect of Ethanol on the Release of Opioids from Oral Prolonged-Release Preparations. Drug Dev. Ind. Pharm. 2007; 33, 1101-1111. Go to original source... Go to PubMed...
    3. Meyer R. J., Hussain A. S. FDA's ACPS Meeting, October 2005, Awareness Topic: Mitigating the Risks of Ethanol Induced Dose Dumping from Oral Sustained/Controlled Release Dosage Forms. http://www.fda.gov/cder/guidance/5194fnl.pdf. (28. 9. 2022).
    4. Food and Drug Administration. FDA/CDER to Osmotica Pharmaceutical Corp. - Petition Partial Approval and Denial. Docket No. FDA-2009-P-0403. https://www.regulations.gov/document/FDA-2009-P-0403-0003 (15. 11. 2022).
    5. Bernstein K. T., Bucciarelli A., Piper T. M., Gross C., Tardiff K., Galea S. Cocaine- and opiate-related fatal overdose in New York City, 1990-2000. BMC Public Health 2007; 7, 11-12. Go to original source... Go to PubMed...
    6. D'Souza S., Mayock S., Salt A. A review of in vivo and in vitro aspects of alcohol-induced dose dumping. AAPS Open 2017; 3, 1-20. Go to original source...
    7. Chari S., Teyssen S., Singer M. V. Alcohol and gastric acid secretion in humans. Gut 1993; 34, 843-847. Go to original source... Go to PubMed...
    8. Fagerberg J. H., Al-Tikriti Y., Ragnarsson G., Bergström C. A. S. Ethanol effects on apparent solubility of poorly soluble drugs in simulated intestinal fluid. Mol. Pharm. 2012; 9, 1942-1952. Go to original source... Go to PubMed...
    9. Orrego-Lagarón N., Martínez-Huélamo M., Vallverdú-Queralt A., Lamuela-Raventos R. M., Escribano-Ferrer E. High gastrointestinal permeability and local metabolism of naringenin: influence of antibiotic treatment on absorption and metabolism. Br. J. Nutr. 2015; 114, 169-180. Go to original source... Go to PubMed...
    10. Evonik Industries GmbH. Eudragit® brochure. https://healthcare.evonik.com/sites/lists/NC/DocumentsHC/Evonik-Eudragit_brochure.pdf (28. 9. 2022). Go to original source...
    11. Mašková E., Kubová K., Vetchý D. Využití (meth)akrylátových kopolymerů v technologii matricových tablet s řízeným uvolňováním. Chem. Listy 2015; 20, 14-20.
    12. Agrawal A. M., Manek R. V., Kolling W. M., Neau S. H. Studies on the interaction of water with ethylcellulose: Effect of polymer particle size. AAPS PharmSciTech, 2003; 4, 2. Go to original source... Go to PubMed...
    13. Wasilewska K., Winnicka K. Ethylcellulose - A Pharmaceutical Excipient with Multidirectional Application in Drug Dosage Forms Development. Materials 2019; 12, 3386. Go to original source... Go to PubMed...
    14. Ghorab M. M., Zia H., Luzzi, L. A. Preparation of controlled release anticancer agents i: 5-fluorouracil-ethyl cellulose microspheres. J. Microencapsul. 1990; 7, 447-454. Go to original source... Go to PubMed...
    15. Rekhi G. S., Jambhekar S. S. Ethylcellulose - a polymer review. Drug Dev. Ind. Pharm. 1995; 21, 61-77. Go to original source...
    16. Jedinger N., Khinast J., Roblegg E. The design of controlled-release formulations resistant to alcohol-induced dose dumping - A review. Eur. J. Pharm. Biopharm. 2014; 87, 217-226. Go to original source... Go to PubMed...
    17. Missaghi S., Fegely K. A., Rajabi-Siahboomi A. R. Investigation of the effects of hydroalcoholic solutions on textural and rheological properties of various controlled release grades of hypromellose. AAPS PharmSciTech. 2009; 10, 77-80. Go to original source... Go to PubMed...
    18. Roberts M., Cespi M., Ford J. L., Dyas A. M., Downing J., Martini L. G., Crowley P. J. Influence of ethanol on aspirin release from hypromellose matrices. Int. J. Pharm. 2007; 332, 31-37. Go to original source... Go to PubMed...
    19. Rahim S., Al-Ghazawi M., Al-Zoubi N. Influence of ethanol on swelling and release behaviors of Carbopol®-based tablets. Pharm. Dev. Technol. 2012; 1-12. Go to original source... Go to PubMed...
    20. Davit B., Braddy A. C., Conner D. P., Yu L. X. International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences. AAPS 2013; 15, 974-990. Go to original source... Go to PubMed...
    21. European Medicines Agency. Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms. EMA/CHMP/EWP/280/96. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmacokinetic-clinical-evaluation-modified-release-dosage-forms_en.pdf (28. 9. 2022).
    22. European Medicines Agency. Quality of medicines questions and answers: Part 2 https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/qa-quality/quality-medicines-questions-answers-part-2 (28. 9. 2022).
    23. Knopf A. Alcohol interactions with prescriptions: Limits of FDA authority. Alcohol. Drug Abus. Wkly. 2019; 31, 4-6. Go to original source...
    24. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Bioavailability Studies Submitted in NDAs or INDs - General Considerations Guidance for Industry. https://www.fda.gov/media/121311/download (28. 9. 2022).
    25. Ann T., Hebestreit G., Faham Y. Regulatory Considerations for Alcohol-Induced Dose Dumping of Oral Modified- Release Formulations. Pharm. Tech. 2015; 38, 40-46.
    26. Downie K., Vagno Pedersen A. Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse. 2010; U.S. Patent Application No 12/523,045.
    27. Palmer D., Levina M., Farrell T. P., Rajabi-Siahboomi A. The influence of hydro-alcoholic media on drug release from polyethylene oxide extended-release matrix tablets. Pharm Technol. 2011; 35, 50-58. Go to original source... Go to PubMed...
    28. Mužiková J., Neprašová M. A Study of Directly Compressible Tableting Materials and Tablets with Two Types of Carbopol® Polymers. Chem. Listy 2014; 108, 237-241.
    29. Rahim S., Al-Ghazawi M., Al-Zoubi N. Influence of ethanol on swelling and release behaviors of Carbopol®-based tablets. Pharm. Dev. Tech. 2013; 18, 1089-1100. Go to original source... Go to PubMed...
    30. Park S. H., Chun M. K., Choi H. K. Preparation of an extended- release matrix tablet using chitosan/Carbopol interpolymer complex. Int. J. Pharm. 2008; 347, 39-44. Go to original source... Go to PubMed...
    31. Levina M., Vuong H., Rajabi-Siahboomi A. R. The influence of hydro-alcoholic media on hypromellose matrix systems. Drug Dev. Ind. Pharm. 2007; 33, 1125-1134. Go to original source... Go to PubMed...
    32. Ghori M. U., Conway B. R. Hydrophilic matrices for oral control drug delivery. Am. J. Pharmacol. Sci. 2015; 5, 103- 109.
    33. Asare-Addo K., Conway B. R., Hajamohaideen M. J., Kaialy W., Nokhodchi A., Larhrib H. Aqueous and hydro-alcoholic media effects on polyols. Colloids Surf. B Biointerfaces 2013; 111, 24-29. Go to original source... Go to PubMed...
    34. Varum F. J. O., Hatton G. B., Basit A. W. Food, physiology and drug delivery. Int. J. Pharm. 2013; 457, 446-460. Go to original source... Go to PubMed...
    35. Koziolek M., Kostewicz E., Vertzoni M. Physiological Considerations and In Vitro Strategies for Evaluating the Influence of Food on Drug Release from Extended-Release Formulations. AAPS PharmSciTech. 2018; 19, 2885-2897. Go to original source... Go to PubMed...
    36. Singh B. N. Effects of food on clinical pharmacokinetics. Clin. Pharmacokinet. 1999; 37, 213-255. Go to original source... Go to PubMed...
    37. Klein S. Predicting Food Effects on Drug Release from Extended-Release Oral Dosage Forms Containing a Narrow Therapeutic Index Drug. Dissolution Technol. 2009; 16, 28-40. Go to original source...
    38. Ramoska E. A., Spiller H. A., Myers A. Calcium channel blocker toxicity. Ann. Emerg. Med. 1990; 19, 649-653. Go to original source... Go to PubMed...
    39. Ueno K., Kawashima S., Uemoto K., Ikada T., Miyai K., Wada K., Nakata I. Effect of Food on Nifedipine Sustained-Release Preparation. DICP 1989; 23, 662- 665. Go to original source... Go to PubMed...
    40. Schug B., Brendel E., Wonnemann M., Wolf D., Wargenau M., Dingler A., Blume H. Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast. Eur. J. Clin. Pharmacol. 2002; 58, 119-125. Go to original source... Go to PubMed...
    41. Wairkar S., Gaud R., Raghavan A. Multi-particulate systems: cutting-edge technology for controlled drug delivery. Recent Pat. Drug Deliv. Formul. 2016; 10, 184- 191. Go to original source... Go to PubMed...
    42. Drugs.com database. Trokendi XR package insert/ prescribing information. https://www.drugs.com/pro/trokendi-xr.html (28. 9. 2022).
    43. The Center for Drug Evaluation and Research, Food and Drug Administration. Clinical pharmacology and biopharmaceutics review(s). Application number 201635Orig1s000. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201635Orig1s000ClinPharmR.pdf (28. 9. 2022).
    44. Food and Drug Administration. Metadate CD Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021259s025lbl.pdf (28. 9. 2022).
    45. Midha K. K., McKay G., Rawson M. J., Korchinski E. D., Hubbard J. W. Effects of Food on the Pharmacokinetics of Methylphenidate. Pharm. Res. 2001; 18, 1185-1189. Go to original source... Go to PubMed...
    46. Modi N. B., Wang B., Hu W. T., Gupta, S. K. Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects. Biopharm. Drug Dispos. 2000; 21, 23-31. Go to original source...
    47. Patrick K. S., Straughn A. B., Jarvi E. J., Breese G. R., Meyer M. C. The absorption of sustained-release methylphenidate formulations compared to an immediate- release formulation. Biopharm. Drug Dispos. 1989; 10, 165-171. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.